Survival is not the only valuable end point in melanoma screening

J Invest Dermatol. 2012 May;132(5):1332-7. doi: 10.1038/jid.2012.3. Epub 2012 Feb 16.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Early Detection of Cancer* / economics
  • False Positive Reactions
  • Health Education
  • Humans
  • Melanoma / diagnosis*
  • Melanoma / mortality
  • Melanoma / pathology
  • Primary Prevention
  • Secondary Prevention
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology